{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:47:27Z","timestamp":1791820047065,"version":"4.3.4"},"reference-count":75,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Concomitant use of antiseizure medications (ASMs) and direct oral anticoagulants (DOACs) is common in epilepsy, but comparative safety data remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare risks of thromboembolic events, major bleeding, and all-cause mortality across commonly used ASMs in adults with epilepsy receiving DOACs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a retrospective cohort study emulating a target trial for each ASM group against an active comparator; 1:1 propensity score matching in 4 cohorts emulated randomization to estimate the per-protocol outcome of sustained ASM monotherapy. Participant data were acquired from the TriNetX Global Collaborative Network, a federated, deidentified electronic health record platform of 165 health care organizations internationally. Included in the study were adults 18 years or older with epilepsy. Individuals were excluded if there was evidence of recent use of vitamin K antagonists (VKAs) or strong non-ASM cytochrome P450 3A4\/P-glycoprotein modulators and if there was a history of major vascular events in the prior year. Participant follow-up began at a prespecified 90-day landmark. Data were analyzed January to March 2026.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n ASM monotherapy with levetiracetam, valproate, moderate enzyme-inducing ASMs, or strong enzyme-inducing ASMs (eg, carbamazepine, phenytoin), each vs lamotrigine or lacosamide (1 pooled reference group of patients taking either drug; hereafter referred to as\n lamotrigine\/lacosamide<\/jats:italic>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes included primary thromboembolic composite (ischemic stroke, myocardial infarction, pulmonary or systemic\/peripheral embolism), major bleeding, and all-cause mortality. Sensitivity analyses included patients treated with VKAs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2.29 million adults (\u226518 years) with epilepsy, 40 932 were DOAC eligible, 26 962 had DOAC-ASM overlap within 6 months, 10 209 were monotherapy eligible, and 9529 initiators formed the analytic cohort. Among 9529 initiators (mean [SD] age, 63 [18] years; 4869 female [51%]), there were 5473 (57%) taking levetiracetam, 1395 (15%) taking strong enzyme-inducing ASMs, 1006 (11%) taking valproate, and 382 (4%) taking moderate enzyme-inducing ASMs. In matched analyses vs lamotrigine\/lacosamide, levetiracetam was associated with higher thromboembolic risk (hazard ratio [HR], 1.98; 95% CI, 1.37-2.87) and higher all-cause mortality (HR, 1.60; 95% CI, 1.23-2.08), with comparable major bleeding. Strong enzyme-inducing ASMs were associated with higher thromboembolic risk (HR, 1.55; 95% CI, 1.02-2.36) but lower major bleeding (HR, 0.62; 95% CI, 0.46-0.83). Valproate was associated with higher mortality (HR, 1.49; 95% CI, 1.09-2.04) and higher intracranial major bleeding (HR, 3.01; 95% CI, 1.45-6.26). Approximately 28% of thromboembolic events were potentially preventable under a lamotrigine\/lacosamide reference. In VKA-treated adults, thromboembolic risks were near null.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results suggest that in adults with epilepsy who are treated with DOACs, ASM selection was associated with distinct thromboembolic, bleeding, and mortality risks, supporting ASM choice as a modifiable contributor to clinical outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2026.2712","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:21Z","timestamp":1786980621000},"page":"1002","source":"Crossref","is-referenced-by-count":0,"title":["Safety of Antiseizure Medications During Direct Oral Anticoagulant Therapy in Epilepsy"],"prefix":"10.1001","volume":"83","author":[{"given":"Kai Michael","family":"Schubert","sequence":"first","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Clinical & Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ferreira-Atuesta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland"},{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunachalam","family":"Soma","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"},{"name":"Liverpool Interdisciplinary Neuroscience Centre, University of Liverpool, Liverpool, United Kingdom"},{"name":"The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Zelano","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden"},{"name":"Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden"},{"name":"Department of Neurology, Sahlgrenska University Hospital, Member of the ERN EpiCARE, Gothenburg, Sweden"},{"name":"Wallenberg Center of Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Seiffge","sequence":"additional","affiliation":[{"name":"Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[{"name":"Innovation, Research and Teaching Service, Teaching Hospital of the Paracelsus Medical Private University, Azienda Sanitaria Dell\u2019Alto Adige, Bolzano-Bozen, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocritical Care, and Neurorehabilitation, Center for Cognitive Neuroscience, Member of European Reference Network EpiCARE, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria"},{"name":"Neuroscience Institute, Center for Cognitive Neuroscience, Christian Doppler University Hospital, Paracelsus Medical University, Salzburg, Austria"},{"name":"Karl Landsteiner Institute for Clinical Neuroscience, Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant K.","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[{"name":"CRUISE, Research Center, Science of Health Department, Magna Grecia University, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom"},{"name":"Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"},{"name":"Department of Cardiology, Lipidology and Internal Medicine with Intensive Coronary Care Unit, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gashirai K","family":"Mbizvo","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom"},{"name":"Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom"},{"name":"Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom"},{"name":"Liverpool Interdisciplinary Neuroscience Centre, University of Liverpool, Liverpool, United Kingdom"},{"name":"The Walton Centre NHS Foundation Trust, Liverpool, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Galovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10172","key":"noi260051r1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults.","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"noi260051r2","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2468-2667(24)00302-5","article-title":"Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"10","author":"GBD Epilepsy Collaborators","year":"2025","journal-title":"Lancet Public Health"},{"issue":"25","key":"noi260051r3","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study.","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"noi260051r4","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1093\/eurheartj\/ehad523","article-title":"Epilepsy and long-term risk of arrhythmias.","volume":"44","author":"Wang","year":"2023","journal-title":"Eur Heart J"},{"issue":"6","key":"noi260051r5","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/epi.18356","article-title":"Epilepsy-heart syndrome: concept, clinical context, and opportunity for integrated care.","volume":"66","author":"Mbizvo","year":"2025","journal-title":"Epilepsia"},{"key":"noi260051r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106946","article-title":"The epileptic heart: concept and clinical evidence.","volume":"105","author":"Verrier","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"10","key":"noi260051r7","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non\u2013vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"noi260051r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107550","article-title":"Trends in oral anticoagulant coprescription with antiepileptic drugs among adults with epilepsy, 2010-2018.","volume":"113","author":"Acton","year":"2020","journal-title":"Epilepsy Behav"},{"key":"noi260051r9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fneur.2018.01067","article-title":"Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs.","volume":"9","author":"Galgani","year":"2018","journal-title":"Front Neurol"},{"issue":"3","key":"noi260051r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100137","article-title":"Drug-drug interactions between direct oral anticoagulants and anticonvulsants and clinical outcomes: a systematic review.","volume":"7","author":"Candeloro","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"noi260051r11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/epd2.20069","article-title":"Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring.","volume":"25","author":"Johannessen Landmark","year":"2023","journal-title":"Epileptic Disord"},{"issue":"6","key":"noi260051r12","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s40120-025-00836-5","article-title":"Safety and effectiveness of direct oral anticoagulants in combination with antiseizure medications: protocol for a systematic review and meta-analysis.","volume":"14","author":"Schubert","year":"2025","journal-title":"Neurol Ther"},{"issue":"4","key":"noi260051r13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40263-025-01163-x","article-title":"Cardiovascular effects of antiseizure medications for epilepsy.","volume":"39","author":"Nei","year":"2025","journal-title":"CNS Drugs"},{"issue":"8","key":"noi260051r14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","article-title":"Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non\u2013vitamin K antagonist oral anticoagulants: a nationwide cohort study.","volume":"9","author":"Grymonprez","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"noi260051r15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2396987317705536","article-title":"European Stroke Organisation guidelines for the management of poststroke seizures and epilepsy.","volume":"2","author":"Holtkamp","year":"2017","journal-title":"Eur Stroke J"},{"issue":"12","key":"noi260051r16","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40263-023-01052-1","article-title":"Levetiracetam interaction with direct oral anticoagulants: a pharmacovigilance study.","volume":"37","author":"Abou Kaoud","year":"2023","journal-title":"CNS Drugs"},{"issue":"8","key":"noi260051r17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamaneurol.2024.2057","article-title":"Direct-acting oral anticoagulants and antiseizure medications for atrial fibrillation and epilepsy and risk of thromboembolic events.","volume":"81","author":"Acton","year":"2024","journal-title":"JAMA Neurol"},{"issue":"1","key":"noi260051r18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40261-020-00982-8","article-title":"Concomitant use of direct oral anticoagulants and antiepileptic drugs: a prospective cohort study in patients with atrial fibrillation.","volume":"41","author":"Giustozzi","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"6","key":"noi260051r19","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study.","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"noi260051r20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1505665","article-title":"Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation.","volume":"16","author":"Huang","year":"2025","journal-title":"Front Pharmacol"},{"issue":"12","key":"noi260051r21","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40263-022-00971-9","article-title":"Thromboembolic risks with concurrent direct oral anticoagulants and antiseizure medications: a population-based analysis.","volume":"36","author":"Ip","year":"2022","journal-title":"CNS Drugs"},{"issue":"7","key":"noi260051r22","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.clinthera.2024.06.002","article-title":"Direct oral anticoagulants and concomitant anti-seizure medications: a retrospective, case-control study in a real-world setting.","volume":"46","author":"Rota","year":"2024","journal-title":"Clin Ther"},{"key":"noi260051r23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10309-024-00708-2","article-title":"Levetiracetam and direct oral anticoagulants\u2014a systematic review.","volume":"38","author":"R\u00f6sche","year":"2024","journal-title":"Clin Epileptol"},{"key":"noi260051r24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.atherosclerosis.2018.11.009","article-title":"Stroke risk and outcomes in epilepsy patients: 2 retrospective cohort studies based on National Health Insurance in Taiwan.","volume":"280","author":"Hsu","year":"2019","journal-title":"Atherosclerosis"},{"issue":"8","key":"noi260051r25","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1111\/epi.18039","article-title":"Safety and efficacy of concomitant treatment with non\u2013vitamin K antagonist oral anticoagulants and antiseizure medications: A propensity score matching cohort study.","volume":"65","author":"Giustozzi","year":"2024","journal-title":"Epilepsia"},{"issue":"3","key":"noi260051r26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjcvp\/pvz035","volume":"6","author":"Wang","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"noi260051r27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MBC.0000000000001342","article-title":"Impact of cytochrome P-450 3A4?enzyme\/P-glycoprotein inducing antiseizure medications on direct oral anticoagulant therapy.","volume":"36","author":"McNary","year":"2025","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"noi260051r28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40263-023-00990-0","article-title":"Interactions between direct oral anticoagulants (DOACs) and antiseizure medications: potential implications on DOAC treatment.","volume":"37","author":"Goldstein","year":"2023","journal-title":"CNS Drugs"},{"issue":"5","key":"noi260051r29","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40263-024-01077-0","article-title":"The effect of levetiracetam compared with enzyme-inducing antiseizure medications on apixaban and rivaroxaban peak plasma concentrations.","volume":"38","author":"Goldstein","year":"2024","journal-title":"CNS Drugs"},{"issue":"12","key":"noi260051r30","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial\u2014the TARGET statement.","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"issue":"10","key":"noi260051r31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000214269","article-title":"Target trial emulation: a primer on improving observational research in neurology.","volume":"105","author":"Terman","year":"2025","journal-title":"Neurology"},{"issue":"8","key":"noi260051r33","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.0000000000000152","article-title":"Target trial emulation to improve causal inference from observational data: what, why, and how?","volume":"34","author":"Fu","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"noi260051r34","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"7624","key":"noi260051r35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"3","key":"noi260051r36","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","article-title":"The target trial framework for causal inference from observational data: why and when is it helpful?","volume":"178","author":"Hern\u00e1n","year":"2025","journal-title":"Ann Intern Med"},{"issue":"1","key":"noi260051r38","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1038\/s41467-025-63469-0","article-title":"A retrospective cohort study of valproate and infertility in men with epilepsy or bipolar disorder using international health data.","volume":"16","author":"Mbizvo","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"noi260051r39","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70198","article-title":"TriNetX Dataworks-USA: overview of a multi-purpose, de-identified, federated electronic health record real-world data and analytics network and comparison to the US Census.","volume":"34","author":"Stein","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"noi260051r40","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7","key":"noi260051r41","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/epi.16547","article-title":"The accuracy of using administrative healthcare data to identify epilepsy cases: a systematic review of validation studies.","volume":"61","author":"Mbizvo","year":"2020","journal-title":"Epilepsia"},{"issue":"6","key":"noi260051r42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1474-4422(21)00075-2","article-title":"Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral hemorrhage: pooled analyses of 2 population-based studies.","volume":"20","author":"Li","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"noi260051r43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/scipharm93030035","article-title":"Risks of oral anticoagulants: interactions with drugs and medicinal plants.","volume":"93","author":"Martins","year":"2025","journal-title":"Sci Pharm"},{"issue":"1","key":"noi260051r44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","article-title":"Observational data for comparative effectiveness research: an emulation of randomized trials of statins and primary prevention of coronary heart disease.","volume":"22","author":"Danaei","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"7","key":"noi260051r45","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/17425255.2025.2510302","article-title":"Drug-drug interaction between anti-seizure medications in Dravet syndrome and Lennox-Gastaut syndrome.","volume":"21","author":"Roberti","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"noi260051r46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/pds.4783","article-title":"Assessment of ICD-10-CM code assignment validity for case finding of outpatient anticoagulant-related bleeding among Medicare beneficiaries.","volume":"28","author":"Shehab","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"noi260051r47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12874-019-0841-6","article-title":"Sensitivity and specificity of an algorithm based on medicoadministrative data to identify hospitalized patients with major bleeding presenting to an emergency department.","volume":"19","author":"Oger","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"noi260051r48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12877-021-02049-5","article-title":"Frailty and hospitalization-associated disability after pneumonia: a prospective cohort study.","volume":"21","author":"Park","year":"2021","journal-title":"BMC Geriatr"},{"issue":"1","key":"noi260051r49","doi-asserted-by":"publisher","first-page":"7966","DOI":"10.1038\/s41598-021-86854-3","article-title":"Frailty is associated with susceptibility and severity of pneumonia in older adults (A JAGES multilevel cross-sectional study).","volume":"11","author":"Iwai-Saito","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"noi260051r50","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s41999-024-00974-3","article-title":"Impact of frailty on pneumonia outcomes in older patients: a systematic review and meta-analysis.","volume":"15","author":"Yang","year":"2024","journal-title":"Eur Geriatr Med"},{"issue":"5","key":"noi260051r51","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/j.1528-1167.2008.01945.x","article-title":"Is a first acute symptomatic seizure epilepsy\u2014mortality and risk for recurrent seizure.","volume":"50","author":"Hesdorffer","year":"2009","journal-title":"Epilepsia"},{"issue":"10","key":"noi260051r52","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.122.060687","article-title":"Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study.","volume":"147","author":"Lawal","year":"2023","journal-title":"Circulation"},{"key":"noi260051r53","doi-asserted-by":"publisher","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non\u2013vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"13","key":"noi260051r54","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation.","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"noi260051r55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching.","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"12","key":"noi260051r56","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ene.14428","article-title":"A neurological point of view on the European Society of Cardiology guidelines: the interactions between direct oral anticoagulants and antiepileptic drugs.","volume":"27","author":"Puma","year":"2020","journal-title":"Eur J Neurol"},{"issue":"46","key":"noi260051r57","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1093\/eurheartj\/ehz657","article-title":"Levetiracetam and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and epilepsy: a reasonable combination.","volume":"40","author":"von Oertzen","year":"2019","journal-title":"Eur Heart J"},{"issue":"3","key":"noi260051r58","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40263-021-00795-z","article-title":"Effect of enzyme-inducing antiseizure medications on the risk of subtherapeutic concentrations of direct oral anticoagulants: a retrospective cohort study.","volume":"35","author":"Perlman","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"noi260051r59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10557-025-07691-4","article-title":"Interactions between direct oral anticoagulants and drugs involving CYP-enzymes and P-gp transporters detected by a clinical decision support system: a retrospective cohort study.","volume":"40","author":"Wuyts","year":"2026","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"noi260051r60","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.amjmed.2021.06.003","article-title":"The impact of strong inducers on direct oral anticoagulant levels.","volume":"134","author":"Sennesael","year":"2021","journal-title":"Am J Med"},{"key":"noi260051r61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2021.09.025","article-title":"Outcomes of direct oral anticoagulants coprescribed with common interacting medications.","volume":"162","author":"Sanborn","year":"2022","journal-title":"Am J Cardiol"},{"issue":"1","key":"noi260051r62","doi-asserted-by":"publisher","first-page":"9257","DOI":"10.1038\/s41598-023-33876-8","article-title":"The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam.","volume":"13","author":"Mavri","year":"2023","journal-title":"Sci Rep"},{"issue":"4","key":"noi260051r63","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cardfail.2021.07.020","article-title":"The relationship between valproate and lamotrigine\/levetiracetam use and prognosis in patients with epilepsy and heart failure: a Danish register-based study.","volume":"28","author":"Liang","year":"2022","journal-title":"J Card Fail"},{"issue":"12","key":"noi260051r64","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1177\/0022034511422909","article-title":"Meta-analysis of dysphagia and aspiration pneumonia in frail elders.","volume":"90","author":"van der Maarel-Wierink","year":"2011","journal-title":"J Dent Res"},{"issue":"10","key":"noi260051r65","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003945.pub4","article-title":"Valproate preparations for agitation in dementia.","volume":"10","author":"Baillon","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"noi260051r66","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1093\/brain\/awae128","article-title":"Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy.","volume":"147","author":"Mbizvo","year":"2024","journal-title":"Brain"},{"issue":"4","key":"noi260051r67","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"3","key":"noi260051r68","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators.","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"noi260051r69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2217\/cer.14.53","article-title":"Revisiting the washout period in the incident user study design: why 6-12 months may not be sufficient.","volume":"4","author":"Roberts","year":"2015","journal-title":"J Comp Eff Res"},{"issue":"6","key":"noi260051r70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4097\/kja.23278","article-title":"Intention-to-treat vs as-treated vs per-protocol approaches to analysis.","volume":"76","author":"Ahn","year":"2023","journal-title":"Korean J Anesthesiol"},{"issue":"11","key":"noi260051r71","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jacc.2024.06.023","article-title":"Competing risks in clinical trials: do they matter and how should we account for them?","volume":"84","author":"Gregson","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"noi260051r72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2288-11-86","article-title":"Understanding competing risks: a simulation point of view.","volume":"11","author":"Allignol","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"noi260051r73","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/aje\/kwae234","article-title":"Use of sensitivity analyses to assess uncontrolled confounding from unmeasured variables in observational, active comparator pharmacoepidemiologic studies: a systematic review.","volume":"194","author":"Latour","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"4","key":"noi260051r74","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"4","key":"noi260051r75","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/01.ede.0000222409.00878.37","article-title":"Instruments for causal inference: an epidemiologist\u2019s dream?","volume":"17","author":"Hern\u00e1n","year":"2006","journal-title":"Epidemiology"},{"key":"noi260051r32","volume-title":"Causal Inference: What If","author":"Hernan","year":"2024"},{"key":"noi260051r37","unstructured":"TriNetX. Home page. Accessed January 6, 2026. https:\/\/trinetx.com\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2853050\/jamaneurology_schubert_2026_oi_260051_1790958460.79527.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:00:27Z","timestamp":1791817227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2853050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":75,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2026.2712","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}